A Efficacy And Safety Analysis Of The Concurrent Chemoradiotherapy In Patients With Stage Ⅰ B-ⅢC Radically Resected Gastric Cancer

Objective：To investigate the efficacy and safety of postoperative chemoradio-therapy compared with postoperative chemotherapy alone in patients with stageⅠＢ-ⅢC radically resected gastric cancer.Methods：A total of75patients were collected from our hospital from Janunly2009to Janunly2010.Among them,42patients received chemoradiotherapyfollowing radical resection.and33patients received chemotherapy alone followingradical resection. The chemotherapy alone arm received eight cycles of mFOLFOX(L-leucovorin400mg/m2, Oxaliplatin130mg/m2, the first day,5-fluorouracil:2.6g/m2,46hours continuous, repeated every3weeks) chemotherapy. Thechemoradiotherapy arm received there cycles of mFOLFOX followed by45-Gy XRT(capecitabine625mg/m2, twice per day for5weeks) and there cycles of mFOLFOX.The1-,2-yr survival rate and1-,2-yr Recurrence-free-survival rate were evaluated,aswell as the hematological and gastrointestinal toxic effects, and hepatic and renalfunction.Result：The1-,2-yr surival rate of the chemoradiotherapy group was88.10％,73.8％,respectively,as compared with72.7％,51,5％in the chemotherapygroup,(P=0.196).The1-,2-yr Recurrence-free-survival rate the chemoradiotherapygroup was83.3％,69％， respectively, as compared with78.8％,60.6％in thechemotherapy group,(P=0.091).The locoregional recurrence occurred in4.8percentof the patients in the chemoradioherapy group and13.8percent of those in thechemotherapy group,(P=0.128). The distant metastasis occurred in31percent ofthe patients in the chemoradioherapy group and33percent of those in thechemotherapy group,(P=0.826). The grade1to2,grade3to4hematologic toxic ofchemoradiotherapy group was57.1％,26.1％,as compared with48.5％,21.2％in thechemotherapy group,(P=0.374). The grade1to2,grade3to4The gastrointestinal toxicof chemoradiotherapy group was66.7％,23.8％,respectively,as compared with69.7 ％,12.1％in the chemotherapy group,(P=0.239).The grade1to2,grade3to4HFS ofchemoradi-otherapy group was21.5％，0％,respectively,as compared with,18.2％，0％,in the chemotherapy group,（P=1.000）.conclusion：Postoperative chemoradiotherapy of patients with stageⅠＢ-ⅢCradically resected gastric cancer improves the1-,2-yr survival rate and1-,2-yrRecurrence-free-survival rate compared with postoperative chemotherapyalone．Although there was no significant difference between the two treatment arms.The toxic effects are tolerable．...